The H6P2W18O62/TiO2composite catalyst was prepared by the combination of nonionic surfactant C18H37(OCH2CH2)10OH(Brij-76)as the template and the sol-gel method.As-synthesized composite was characterized by FT-TR,SEM,N...The H6P2W18O62/TiO2composite catalyst was prepared by the combination of nonionic surfactant C18H37(OCH2CH2)10OH(Brij-76)as the template and the sol-gel method.As-synthesized composite was characterized by FT-TR,SEM,N2 absorption-desorption and NH3-TPD.The results showed that the composite H6P2W18O62/TiO2 was mesoporous material(ca.3.3 nm),and large surface area(99.78 m2/g).Additionally,the aggregation of TiO2 particles was effectively inhibited,and the surface acidity was increased substantially.The photocatalytic elimination of monochlorobenzene was used as model reaction to evaluate the photocatalytic activity of the composite catalyst under visible light separately.Photocatalytic experimental results showed that the composite H6P2W18O62/TiO2 can effectively degradate monochlorobenzene.展开更多
目的探讨细胞色素P450酶2W1(cytochrome P450 family 2 subfamily W member 1,CYP2W1)、微小RNA-491-5p(microRNA-491-5p,miR-491-5p)在肝细胞癌(hepatocellular cancer,HCC)组织中的表达与临床病理特征的关系和预后的相关性分析。方法...目的探讨细胞色素P450酶2W1(cytochrome P450 family 2 subfamily W member 1,CYP2W1)、微小RNA-491-5p(microRNA-491-5p,miR-491-5p)在肝细胞癌(hepatocellular cancer,HCC)组织中的表达与临床病理特征的关系和预后的相关性分析。方法选取2019年2月~2021年2月在我院进行手术治疗的120例HCC作为研究对象,手术过程中取HCC组织和癌旁组织标本。实时荧光定量PCR(qRT-PCR)法检测mRNA表达水平,免疫组化法检测蛋白表达水平。分析HCC组织和癌旁组织中miR-491-5p与CYP2W1 mRNA表达的差异及二者表达与患者临床病理特征的相关性,并做Kaplan-Meier生存分析曲线。结果HCC组织中CYP2W1 mRNA表达水平显著高于癌旁组织,miR-491-5p表达水平显著低于癌旁组织(P<0.05);HCC组织中CYP2W1蛋白阳性表达率显著高于癌旁组织(χ^(2)=23.721,P<0.001)。HCC组织中miR-491-5p与CYP2W1 mRNA表达水平呈负相关(r=-0.417,P<0.001)。CYP2W1、miR-491-5p表达与HCC患者TNM分期、肿瘤分化程度、淋巴结转移和病理分级存在显著相关性(P<0.05)。Kaplan-Meier生存分析曲线显示,CYP2W1阳性表达组3年累积生存率为31.4%,低于CYP2W1阴性表达组的63.8%(log-rankχ^(2)=12.243,P=0.000);miR-491-5p高表达组3年累积生存率为61.3%,显著高于miR-491-5p低表达组的37.9%(log-rankχ^(2)=4.490,P=0.034)。复发组HCC组织中CYP2W1 mRNA表达水平显著高于未复发组,miR-491-5p表达水平显著低于未复发组(P<0.05);转移组HCC组织中CYP2W1 mRNA表达水平显著高于未转移组,miR-491-5p表达水平显著低于未转移组(P<0.05)。结论HCC组织中CYP2W1高表达,miR-491-5p低表达,二者与HCC患者的部分临床病理特征和预后存在显著相关性。展开更多
文摘The H6P2W18O62/TiO2composite catalyst was prepared by the combination of nonionic surfactant C18H37(OCH2CH2)10OH(Brij-76)as the template and the sol-gel method.As-synthesized composite was characterized by FT-TR,SEM,N2 absorption-desorption and NH3-TPD.The results showed that the composite H6P2W18O62/TiO2 was mesoporous material(ca.3.3 nm),and large surface area(99.78 m2/g).Additionally,the aggregation of TiO2 particles was effectively inhibited,and the surface acidity was increased substantially.The photocatalytic elimination of monochlorobenzene was used as model reaction to evaluate the photocatalytic activity of the composite catalyst under visible light separately.Photocatalytic experimental results showed that the composite H6P2W18O62/TiO2 can effectively degradate monochlorobenzene.
文摘目的探讨细胞色素P450酶2W1(cytochrome P450 family 2 subfamily W member 1,CYP2W1)、微小RNA-491-5p(microRNA-491-5p,miR-491-5p)在肝细胞癌(hepatocellular cancer,HCC)组织中的表达与临床病理特征的关系和预后的相关性分析。方法选取2019年2月~2021年2月在我院进行手术治疗的120例HCC作为研究对象,手术过程中取HCC组织和癌旁组织标本。实时荧光定量PCR(qRT-PCR)法检测mRNA表达水平,免疫组化法检测蛋白表达水平。分析HCC组织和癌旁组织中miR-491-5p与CYP2W1 mRNA表达的差异及二者表达与患者临床病理特征的相关性,并做Kaplan-Meier生存分析曲线。结果HCC组织中CYP2W1 mRNA表达水平显著高于癌旁组织,miR-491-5p表达水平显著低于癌旁组织(P<0.05);HCC组织中CYP2W1蛋白阳性表达率显著高于癌旁组织(χ^(2)=23.721,P<0.001)。HCC组织中miR-491-5p与CYP2W1 mRNA表达水平呈负相关(r=-0.417,P<0.001)。CYP2W1、miR-491-5p表达与HCC患者TNM分期、肿瘤分化程度、淋巴结转移和病理分级存在显著相关性(P<0.05)。Kaplan-Meier生存分析曲线显示,CYP2W1阳性表达组3年累积生存率为31.4%,低于CYP2W1阴性表达组的63.8%(log-rankχ^(2)=12.243,P=0.000);miR-491-5p高表达组3年累积生存率为61.3%,显著高于miR-491-5p低表达组的37.9%(log-rankχ^(2)=4.490,P=0.034)。复发组HCC组织中CYP2W1 mRNA表达水平显著高于未复发组,miR-491-5p表达水平显著低于未复发组(P<0.05);转移组HCC组织中CYP2W1 mRNA表达水平显著高于未转移组,miR-491-5p表达水平显著低于未转移组(P<0.05)。结论HCC组织中CYP2W1高表达,miR-491-5p低表达,二者与HCC患者的部分临床病理特征和预后存在显著相关性。
基金2013年国家级大学生创新创业训练计划项目(201313256001)湖北师范学院硕士研究生创新科研基金项目(1051320130216)+1 种基金National Undergraduate Training Programs for Innovation and Entrepreneurship(201313256001)Postgraduate Innovation Scientific Research Foundation of Hubei Normal University(1051320130216)
